ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 33479224

Hepatocellular carcinoma.

Llovet JM and 9 others. Nat Rev Dis Primers, 2021. Cited by 5,644 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Hepatocellular carcinoma. Papers, record 33479224. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33479224

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Hepatocellular carcinoma.
PubMed
Journal
Nat Rev Dis Primers
PubMed
Year
2021
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Review
PubMed
Citations, by iCite
5,644
iCite
Relative citation ratio, by iCite
375
iCite
Revised in PubMed
2026-09-03
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Llovet JMJosep Mhttps://orcid.org/0000-0003-0547-2667
2Kelley RKRobin Kate
3Villanueva AAugustohttps://orcid.org/0000-0003-3585-3727
4Singal AGAmit G
5Pikarsky EEli
6Roayaie SSasan
7Lencioni RRiccardo
8Koike KKazuhiko
9Zucman-Rossi JJessicahttps://orcid.org/0000-0002-5687-0334
10Finn RSRichard S

Source PubMed

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, HepatocellularMajor topic
Liver NeoplasmsMajor topic
Combined Modality Therapy
Humans
Immunotherapy
Sorafenib

Source PubMed

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA196521NCI NIH HHSUnited StatesP30CA196521PubMed and NIHNIH RePORTER
C9380/A26813Cancer Research UKUnited KingdomPubMedPubMed

Trials11

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT05171166Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.BackgroundClinicalTrials.gov
NCT05242237Prognostic Value of Liver Cancer CTCs Isolated by a Novel Microfluidic PlatformResultsClinicalTrials.gov
NCT05278195Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging BiomarkersBackgroundClinicalTrials.gov
NCT05332496TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCCBackgroundClinicalTrials.gov
NCT05332821TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCCBackgroundClinicalTrials.gov
NCT06096896The Efficacy and Safety of EOB-MRI Guided Microwave Ablation for Early HCC: A Multicenter, Prospective, Observational StudyResultsClinicalTrials.gov
NCT06355700Hepatocellular Carcinoma Liver OrganoidsBackgroundClinicalTrials.gov
NCT07265271Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)BackgroundClinicalTrials.gov
NCT07493668Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line ImmunotherapyBackgroundClinicalTrials.gov
NCT07774247Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular CarcinomaBackgroundClinicalTrials.gov

1 to 10 of 11

See all 11 trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in38,346,997Author Correction: Hepatocellular carcinoma.https://conductscience.org/library/papers/38346997

Source PubMed

References289

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129,508,855Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.Nat Rev Clin Oncol2018https://conductscience.org/library/papers/29508855PubMed
215,042,359Randomized controlled trial of screening for hepatocellular carcinoma.J Cancer Res Clin Oncol2004https://conductscience.org/library/papers/15042359PubMed
330,445,016Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy-A Systematic Review.Gastroenterology2019https://conductscience.org/library/papers/30445016PubMed
410,573,522Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation.Hepatology1999https://conductscience.org/library/papers/10573522PubMed
528,453,431Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series.Radiology2017https://conductscience.org/library/papers/28453431PubMed
631,421,157Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.J Hepatol2019https://conductscience.org/library/papers/31421157PubMed
726,301,494Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas.Nat Genet2015https://conductscience.org/library/papers/26301494PubMed
831,954,489Novel patient-derived preclinical models of liver cancer.J Hepatol2020https://conductscience.org/library/papers/31954489PubMed
918,650,514Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008https://conductscience.org/library/papers/18650514PubMed
1026,628,466Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.J Clin Oncol2016https://conductscience.org/library/papers/26628466PubMed

1 to 10 of 289

See all 289 references

Cited by4,285

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5,644 citations.

PMIDTitleJournalYearIn PapersSource
42,985,384Cancer-Associated Fibroblasts-Orchestrated Immune Remodeling as a Key Driver in Liver Cancer.Oncol Res2026https://conductscience.org/library/papers/42985384PubMed
42,983,723Loss of FCN3 links cirrhotic matrix stiffness to YAP activation in HCC.J Transl Med2026https://conductscience.org/library/papers/42983723PubMed
42,980,729Feasibility of one-stop multi-energy dynamic photon-counting perfusion CT for resectable HCC evaluation: lesion detection and histopathological correlations.Insights Imaging2026https://conductscience.org/library/papers/42980729PubMed
42,978,941SPP1 promotes anoikis resistance and metastatic phenotypes in hepatocellular carcinoma through PI3K-sensitive signaling.Front Immunol2026https://conductscience.org/library/papers/42978941PubMed
42,978,668Editorial: Liver diseases - from pathophysiology to new treatment options.Front Immunol2026https://conductscience.org/library/papers/42978668PubMed
42,977,53118F-FGln PET/CT Imaging of Glutamine Uptake Has Potential for Predicting Immunotherapy Response in Hepatocellular Carcinoma.Adv Sci (Weinh)2026https://conductscience.org/library/papers/42977531PubMed
42,976,211PIVKA-II and hematological parameters in hepatocellular carcinoma and non-malignant chronic liver disease: A case-control biomarker comparison in a hepatitis-endemic population.PLoS One2026https://conductscience.org/library/papers/42976211PubMed
42,975,755Dynamic contrast-enhanced MRI and tumor microenvironment in hepatocellular carcinoma: exploratory analysis of CD3 + TILs, PD-L1, and glypican-3.Eur Radiol Exp2026https://conductscience.org/library/papers/42975755PubMed
42,974,461A Combined Ki-67 and Microvascular Invasion Score Predicts Early Recurrence and Survival After Hepatectomy for HCC.J Hepatocell Carcinoma2026https://conductscience.org/library/papers/42974461PubMed
42,974,131Association of Hepatitis B and Hepatitis C Virus Infections With Hepatocellular Carcinoma: A Systematic Review of Virological, Histopathological, and Molecular Evidence.Cureus2026https://conductscience.org/library/papers/42974131PubMed

1 to 10 of 4,285

See all 4,285 cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
VEGFA7,422PubTator's text mininghttps://conductscience.org/library/genes/7422

Source NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33479224

GET https://conductscience.org/api/papers/v1/33479224/references?page=2

API referenceFor AI assistants